Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ADRB2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CARVEDILOL | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1257092 | ? unclear | Mechanistic | DGIdb | |
| SODIUM CHLORIDE | ? unclear | Mechanistic | DGIdb | |
| PENBUTOLOL SULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| DESIPRAMINE | ? unclear | Mechanistic | DGIdb | |
| METIPRANOLOL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL531322 | ? unclear | Mechanistic | DGIdb | |
| NADOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| PIRBUTEROL | ? unclear | Mechanistic | DGIdb | |
| FENOTEROL | ↑ activates | Mechanistic | DGIdb | |
| TIMOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| ABEDITEROL | ↑ activates | Mechanistic | DGIdb | |
| PINDOLOL | ↑ activates | Mechanistic | DGIdb | |
| BRONCHODILATOR | ? unclear | Mechanistic | DGIdb | |
| TULOBUTEROL | ↑ activates | Mechanistic | DGIdb | |
| PHENYLEPHRINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| GSK159802 | ↑ activates | Mechanistic | DGIdb | |
| PRILOCAINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CLENBUTEROL | ↑ activates | Mechanistic | DGIdb | |
| PROPRANOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| INDACATEROL MALEATE | ↑ activates | Mechanistic | DGIdb | |
| VILANTEROL | ? unclear | Mechanistic | DGIdb | |
| TERTATOLOL | ? unclear | Mechanistic | DGIdb | |
| ARFORMOTEROL | ↑ activates | Mechanistic | DGIdb | |
| INDACATEROL | ? unclear | Mechanistic | DGIdb | |
| FORMOTEROL FUMARATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL111201 | ? unclear | Mechanistic | DGIdb | |
| RITODRINE | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL599896 | ? unclear | Mechanistic | DGIdb | |
| VILANTEROL TRIFENATATE | ↑ activates | Mechanistic | DGIdb | |
| RITODRINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| DISULFIRAM | ? unclear | Mechanistic | DGIdb | |
| BUCINDOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| LEVALBUTEROL TARTRATE | ↑ activates | Mechanistic | DGIdb | |
| LAS190792 | ↑ activates | Mechanistic | DGIdb | |
| ALPRENOLOL | ? unclear | Mechanistic | DGIdb | |
| CELIPROLOL | ↑ activates | Mechanistic | DGIdb | |
| ALBUTEROL SULFATE | ↑ activates | Mechanistic | DGIdb | |
| CARTEOLOL | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 148 agents ranked by evidence tier.
ALOX5
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| BALSALAZIDE | ? unclear | Mechanistic | DGIdb | |
| MASOPROCOL | ? unclear | Mechanistic | DGIdb | |
| DARBUFELONE | ? unclear | Mechanistic | DGIdb | |
| MECLOFENAMATE | ? unclear | Mechanistic | DGIdb | |
| CGP 47656 | ↑ activates | Mechanistic | DGIdb | |
| TEPOXALIN | ↓ inhibits | Mechanistic | DGIdb | |
| MESALAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL416038 | ? unclear | Mechanistic | DGIdb | |
| PF-4191834 | ↓ inhibits | Mechanistic | DGIdb | |
| PTC299 | ? unclear | Mechanistic | DGIdb | |
| MELATONIN | ? unclear | Mechanistic | DGIdb | |
| MECLOFENAMATE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| MONTELUKAST SODIUM | ? unclear | Mechanistic | DGIdb | |
| BALSALAZIDE DISODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| LESOGABERAN | ↑ activates | Mechanistic | DGIdb | |
| ATRELEUTON | ? unclear | Mechanistic | DGIdb | |
| RILOPIROX | ? unclear | Mechanistic | DGIdb | |
| 6BIO | ? unclear | Mechanistic | DGIdb | |
| ZILEUTON | ↓ inhibits | Mechanistic | 3300.0 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL502496 | ? unclear | Mechanistic | DGIdb | |
| TENIDAP | ? unclear | Mechanistic | DGIdb | |
| SULFASALAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| DIETHYLCARBAMAZINE | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| OLSALAZINE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ACACETIN | ? unclear | Mechanistic | DGIdb | |
| LICOFELONE | ? unclear | Mechanistic | DGIdb | |
| TIPELUKAST | ? unclear | Mechanistic | DGIdb | |
| 5-OXO-ETE | ? unclear | Mechanistic | DGIdb | |
| METHOTREXATE | ? unclear | Mechanistic | DGIdb | |
| SILYMARIN | ? unclear | Mechanistic | DGIdb | |
| ANACARDIC ACID | ? unclear | Mechanistic | DGIdb | |
| MECLOFENAMIC ACID | ? unclear | Mechanistic | Open Targets | |
| OLSALAZINE | ? unclear | Mechanistic | Open Targets | |
| CHEMBL26083 | ↓ inhibits | Mechanistic | 2500.0 nM (IC50) | ChEMBL |
| CHEMBL25790 | ↓ inhibits | Mechanistic | 6000.0 nM (IC50) | ChEMBL |
| CHEMBL38172 | ↓ inhibits | Mechanistic | 90.0 nM (IC50) | ChEMBL |
| CHEMBL444315 | ↓ inhibits | Mechanistic | 30.0 nM (IC50) | ChEMBL |
| CHEMBL29874 | ↓ inhibits | Mechanistic | 39000.0 nM (IC50) | ChEMBL |
Showing top 40 of 181 agents ranked by evidence tier.
CYSLTR1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PRANLUKAST | ↓ inhibits | Mechanistic | 0.8 nM (IC50) | DGIdb |
| NEDOCROMIL | ? unclear | Mechanistic | DGIdb | |
| CR-3465 | ↓ inhibits | Mechanistic | DGIdb | |
| CINALUKAST | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL314115 | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT TRANSFORMING GROWTH FACTOR-BETA 1 | ? unclear | Mechanistic | DGIdb | |
| MASILUKAST | ? unclear | Mechanistic | DGIdb | |
| LY-2300559 | ? unclear | Mechanistic | DGIdb | |
| ZAFIRLUKAST | ↓ inhibits | Mechanistic | 1.731 nM (IC50) | DGIdb |
| MONTELUKAST SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| IRALUKAST | ? unclear | Mechanistic | DGIdb | |
| MONTELUKAST | ? unclear | Mechanistic | 0.5 nM (IC50) | Open Targets |
| SR-2640 | ↓ inhibits | Mechanistic | 23.0 nM (IC50) | ChEMBL |
| CHEMBL89340 | ↓ inhibits | Mechanistic | 3.1 nM (IC50) | ChEMBL |
| ABLUKAST | ↓ inhibits | Mechanistic | 4000.0 nM (IC50) | ChEMBL |
| FPL-55712 | ↓ inhibits | Mechanistic | 4000.0 nM (IC50) | ChEMBL |
| CHEMBL89768 | ↓ inhibits | Mechanistic | 3.1 nM (IC50) | ChEMBL |
| VERLUKAST | ↓ inhibits | Mechanistic | 8.0 nM (IC50) | ChEMBL |
| POBILUKAST | ↓ inhibits | Mechanistic | 10.0 nM (Ki) | ChEMBL |
| CHEMBL97356 | ↓ inhibits | Mechanistic | 11.0 nM (Ki) | ChEMBL |
| CHEMBL313177 | ↓ inhibits | Mechanistic | 6.42 nM (IC50) | ChEMBL |
| CHEMBL316170 | ↓ inhibits | Mechanistic | 1.06 nM (IC50) | ChEMBL |
| CHEMBL82790 | ↓ inhibits | Mechanistic | 4.7 nM (IC50) | ChEMBL |
| CHEMBL84707 | ↓ inhibits | Mechanistic | 1.91 nM (IC50) | ChEMBL |
| CHEMBL86264 | ↓ inhibits | Mechanistic | 8.49 nM (IC50) | ChEMBL |
| CHEMBL87528 | ↓ inhibits | Mechanistic | 3.36 nM (IC50) | ChEMBL |
| CHEMBL314340 | ↓ inhibits | Mechanistic | 1.16 nM (IC50) | ChEMBL |
| CHEMBL314237 | ↓ inhibits | Mechanistic | 0.76 nM (IC50) | ChEMBL |
| CHEMBL83233 | ↓ inhibits | Mechanistic | 15.7 nM (IC50) | ChEMBL |
| CHEMBL86063 | ↓ inhibits | Mechanistic | 0.72 nM (IC50) | ChEMBL |
| CHEMBL86302 | ↓ inhibits | Mechanistic | 1.63 nM (IC50) | ChEMBL |
| CHEMBL313195 | ↓ inhibits | Mechanistic | 0.47 nM (IC50) | ChEMBL |
| CHEMBL85572 | ↓ inhibits | Mechanistic | 2.43 nM (IC50) | ChEMBL |
| CHEMBL85633 | ↓ inhibits | Mechanistic | 2.01 nM (IC50) | ChEMBL |
| CHEMBL84841 | ↓ inhibits | Mechanistic | 8.67 nM (IC50) | ChEMBL |
| CHEMBL313187 | ↓ inhibits | Mechanistic | 0.38 nM (IC50) | ChEMBL |
| CHEMBL414885 | ↓ inhibits | Mechanistic | 0.65 nM (IC50) | ChEMBL |
| CHEMBL87696 | ↓ inhibits | Mechanistic | 2.16 nM (IC50) | ChEMBL |
| CHEMBL87337 | ↓ inhibits | Mechanistic | 0.55 nM (IC50) | ChEMBL |
| CHEMBL315973 | ↓ inhibits | Mechanistic | 1.05 nM (IC50) | ChEMBL |
Showing top 40 of 189 agents ranked by evidence tier.
FCER1A
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| BENZYLPENICILLOYL POLYLYSINE | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 27D [PMID: 28231433] | ↓ inhibits | Mechanistic | DGIdb | |
| OPAGANIB | ↓ inhibits | Mechanistic | DGIdb | |
| PF-543 | ↓ inhibits | Mechanistic | DGIdb | |
| SKI II | ↓ inhibits | Mechanistic | DGIdb | |
| ROME | ↓ inhibits | Mechanistic | DGIdb | |
| MP-A08 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 55 [PMID: 30889352] | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 49 [PMID: 30889352] | ↓ inhibits | Mechanistic | DGIdb | |
| OMALIZUMAB | ? unclear | Mechanistic | DGIdb | |
| SLC4101431 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 60 [PMID: 30889352] | ↓ inhibits | Mechanistic | DGIdb | |
| SLM6071469 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 59 [PMID: 30889352] | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL275575 | ↓ inhibits | Mechanistic | 71000.0 nM (IC50) | ChEMBL |
| CHEMBL412391 | ↓ inhibits | Mechanistic | 25000.0 nM (IC50) | ChEMBL |
| CHEMBL267118 | ↓ inhibits | Mechanistic | 82000.0 nM (IC50) | ChEMBL |
GATA3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| DEXAMETHASONE | ? unclear | Mechanistic | DGIdb | |
| METHOTREXATE | ? unclear | Mechanistic | DGIdb | |
| ASPARAGINASE | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ↓ inhibits | Mechanistic | DGIdb | |
| MYCOPHENOLATE MOFETIL | ↓ inhibits | Mechanistic | DGIdb | |
| PEGASPARGASE | ? unclear | Mechanistic | DGIdb | |
| MYCOPHENOLATE | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| VINCRISTINE | ? unclear | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| PREDNISONE | ? unclear | Mechanistic | DGIdb | |
| LEUCOVORIN CALCIUM | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| THIOGUANINE | ↓ inhibits | Mechanistic | DGIdb | |
| MERIMEPODIB | ↓ inhibits | Mechanistic | DGIdb | |
| GLUCARPIDASE | ? unclear | Mechanistic | DGIdb | |
| DAUNORUBICIN LIPOSOMAL | ? unclear | Mechanistic | DGIdb | |
| MERCAPTOPURINE | ? unclear | Mechanistic | DGIdb |
IL13
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DECTREKUMAB | ? unclear | Mechanistic | DGIdb | |
| TRALOKINUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| QAX-576 | ↓ inhibits | Mechanistic | DGIdb | |
| ROMILKIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CENDAKIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ? unclear | Mechanistic | DGIdb | |
| TNX-650 | ↓ inhibits | Mechanistic | DGIdb | |
| USTEKINUMAB | ? unclear | Mechanistic | DGIdb | |
| LEBRIKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CNTO-5825 | ↓ inhibits | Mechanistic | DGIdb | |
| ANRUKINZUMAB | ↓ inhibits | Mechanistic | DGIdb |
IL13RA1
IL1RL1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASTEGOLIMAB | ↓ inhibits | Mechanistic | DGIdb |
IL33
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASTEGOLIMAB | ? unclear | Mechanistic | DGIdb | |
| TORUDOKIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ETOKIMAB | ~ modulates | Mechanistic | DGIdb | |
| ITEPEKIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL5270750 | ↓ inhibits | Mechanistic | 43000.0 nM (IC50) | ChEMBL |
| CHEMBL5276831 | ↓ inhibits | Mechanistic | 42000.0 nM (IC50) | ChEMBL |
IL4R
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SUNITINIB | ? unclear | Mechanistic | DGIdb | |
| CINTREDEKIN BESUDOTOX | ~ modulates | Mechanistic | DGIdb | |
| PITRAKINRA | ? unclear | Mechanistic | DGIdb | |
| DUPILUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BIZAXOFUSP | ? unclear | Mechanistic | DGIdb | |
| ROMILKIMAB | ? unclear | Mechanistic | DGIdb |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METHYLPREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| ADENOVIRUS VECTOR | ? unclear | Mechanistic | DGIdb | |
| BENRALIZUMAB | ? unclear | Mechanistic | DGIdb | |
| RESLIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| DEPEMOKIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| INTERLEUKIN-3 | ? unclear | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| MEPOLIZUMAB | ↓ inhibits | Mechanistic | DGIdb |
IL5RA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| BENRALIZUMAB | ↓ inhibits | Mechanistic | DGIdb |
MS4A2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TIRBANIBULIN | ↓ inhibits | Mechanistic | DGIdb | |
| CCT196969 | ↓ inhibits | Mechanistic | DGIdb | |
| N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE | ↓ inhibits | Mechanistic | DGIdb | |
| KX2-361 | ↓ inhibits | Mechanistic | DGIdb | |
| (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PD166285 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 36 [PMID: 21958547] | ↓ inhibits | Mechanistic | DGIdb | |
| GEMCITABINE | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 25 [PMID: 31260299] | ↓ inhibits | Mechanistic | DGIdb | |
| ELZOVANTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| SYK INHIBITOR III | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 8H [PMID: 22765894] | ↓ inhibits | Mechanistic | DGIdb | |
| MAX-40279 | ↓ inhibits | Mechanistic | DGIdb | |
| ACALABRUTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| SI306 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 19A [PMID: 30503936] | ↓ inhibits | Mechanistic | DGIdb | |
| NG-25 | ↓ inhibits | Mechanistic | DGIdb | |
| DASATINIB ANHYDROUS | ↓ inhibits | Mechanistic | DGIdb | |
| ECF506 | ↓ inhibits | Mechanistic | DGIdb | |
| CCT241161 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 2 [PMID: 15546730] | ↓ inhibits | Mechanistic | DGIdb | |
| PP-121 | ↓ inhibits | Mechanistic | DGIdb | |
| SARACATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| BOSUTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| DORSOMORPHIN | ↓ inhibits | Mechanistic | DGIdb | |
| BALAMAPIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| IBRUTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| TAK-020 | ↓ inhibits | Mechanistic | DGIdb | |
| ENMD-2076 | ↓ inhibits | Mechanistic | DGIdb | |
| WH-4-023 | ↓ inhibits | Mechanistic | DGIdb | |
| OMALIZUMAB | ? unclear | Mechanistic | DGIdb |
TSLP
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Asthma: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at ...
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could h...
The goal of this clinical trial is to learn if drug HB0056 works to treat severe asthma in adults. It will also learn about the safety of drugHB0056. The main questions it aims to answer are: Does drug HB0056 lower the number of times participants need to use a rescue inhaler? What medical problems ...
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerabili...
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary disease (COPD). ⚠️study will only be conducted in research centers in Brazil...
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma....
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (...
The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
This is a global Phase 2 study divided in two parts. Part A is a double-blind, randomized dose-range finding study in adults with moderate to severe asthma to confirm the dosing regimen of WIN378 that can be tested in future pivotal trials for efficacy and safety. Part B is a pivotal double-blind, r...
Phase III clinical study of SIM0718 asthma
The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
Agents Found By Disease-Level Search
Searched directly from “Asthma” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 15-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
42 agents shown (approved or with trial evidence) — 39 not found by the gene-target search above.
Mometasone furoateNOT in gene-target list
Fluticasone propionateNOT in gene-target list
Fluticasone furoateNOT in gene-target list
SpirivaNOT in gene-target list
Fixed combination of budesonide and formoterolNOT in gene-target list
BudesonideNOT in gene-target list
Formoterol fumerateNOT in gene-target list
fenoterol/ipratropium bromideNOT in gene-target list
budesonide/formoterol TurbuhalerNOT in gene-target list
stapokibart (CM310)NOT in gene-target list
CHF5993 pMDI with HFA-152aNOT in gene-target list
CHF5993 pMDI with HFA-134aNOT in gene-target list
CHF718 pMDI with HFA-134aNOT in gene-target list
IBI3002NOT in gene-target list
SB010NOT in gene-target list
Open Airways for SchoolsNOT in gene-target list
OXIMAXNOT in gene-target list
ASMANEX TWISTHALERNOT in gene-target list
IgE adsorberNOT in gene-target list
Administration of inhaled tiotropium bromideNOT in gene-target list
Formoterol Fumarate
HEPA Air CleanerNOT in gene-target list
Single Inhalation techniqueNOT in gene-target list
Tidal inhalation techniqueNOT in gene-target list
Postcard and IVR Reminder GroupNOT in gene-target list
Postcard Only Reminder GroupNOT in gene-target list
IVR Only Reminder GroupNOT in gene-target list
AlfacalcidolNOT in gene-target list
AER 001NOT in gene-target list
Smart inhalerNOT in gene-target list
SHR-1703 InjectionNOT in gene-target list
BENRALIZUMAB
QVM149NOT in gene-target list
Salmeterol/fluticasone plus tiotropiumNOT in gene-target list
Ginger ExtractNOT in gene-target list
Prick testsNOT in gene-target list
FP 100NOT in gene-target list
GSK2190915 100NOT in gene-target list
GSK2190915 300NOT in gene-target list
montelukast
FP/SAL 100/50NOT in gene-target list
Use of smart inhaler to enhance asthma inhaler proficiencyNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.